Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

Fast and accurate short read alignment with Burrows-Wheeler transform

Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.

Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849

Mapping and quantifying mammalian transcriptomes by RNA-Seq

Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696

Primer3—new capabilities and interfaces

Untergasser, A., Cutcutache, I., Kõressaar, T., Ye, J., Faircloth, B., Remm, M., & Rozen, S. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks596 · Cited by 9,165

Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration

Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049

<tt>BLAT</tt> —The <tt>BLAST</tt> -Like Alignment Tool

Kent, W. J. (2002) · Genome Research · doi:10.1101/gr.229202 · Cited by 8,480

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887

Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity

Mosaheb, M., Dobrikova, E. Y., Brown, M. C., Yang, Y., Cable, J. M., Okada, H., Nair, S. K., Bigner, D. D., Ashley, D. M., & Gromeier, M. (2020) · Nature Communications · doi:10.1038/s41467-019-13939-z · Cited by 36

Nanotherapeutics for Immuno-Oncology: A Crossroad for New Paradigms

Song, W., Das, M., & Chen, X. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.01.011 · Cited by 38

Promising RNA-based cancer gene therapy using extracellular vesicles for drug delivery

Xue, V. W., Wong, S. C. C., Song, G., & Cho, W. C. S. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1738377 · Cited by 37

Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers

Acebes-Fernández, V., Landeira‐Viñuela, A., Juanes‐Velasco, P., Hernández, Á., Otazo‐Pérez, A., Manzano-Román, R., Góngora, R., & Fuentes, M. (2020) · Nanomaterials · doi:10.3390/nano10071274 · Cited by 39

Discovery through clinical sequencing in oncology

Donoghue, M. T. A., Schram, A. M., Hyman, D. M., & Taylor, B. S. (2020) · Nature Cancer · doi:10.1038/s43018-020-0100-0 · Cited by 38

Challenges targeting cancer neoantigens in 2021: a systematic literature review

Chen, I., Chen, M. Y., Goedegebuure, S. P., & Gillanders, W. E. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1935248 · Cited by 39

Clinical and Translational Advances in Glioma Immunotherapy

Bunse, L., Bunse, T., Krämer, C., Chih, Y., & Platten, M. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01313-9 · Cited by 40

Umbilical artery acid-base status in the preterm infant.

Ramin, S. M., Gilstrap, L. C., Leveno, K. J., Burris, J., & Little, “. B. B. (1989) · PubMed · Cited by 37

In Cellulo and In Vivo Comparison of Cholesterol, Beta-Sitosterol and Dioleylphosphatidylethanolamine for Lipid Nanoparticle Formulation of mRNA

Medjmedj, A., Loth, A. N., Clémençon, R., Hamáček, J., Pichon, C., & Perche, F. (2022) · Nanomaterials · doi:10.3390/nano12142446 · Cited by 39

Personalised neoantigen‐based therapy in colorectal cancer

Zhu, Y., Li, X., Chen, T., Wang, J., Zhou, Y., Mu, X., Du, Y., Wang, J., Tang, J., & Liu, J. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1461 · Cited by 37

Liposomal Nanostructures for Drug Delivery in Gastrointestinal Cancers

Das, M., & Huang, L. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.254797 · Cited by 37

Immunotherapy in Ovarian Cancer

Wang, W., Liu, J. R., & Zou, W. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.02.002 · Cited by 36

Melanoma-Secreted Lysosomes Trigger Monocyte-Derived Dendritic Cell Apoptosis and Limit Cancer Immunotherapy

Santana-Magal, N., Farhat-Younis, L., Gutwillig, A., Gleiberman, A., Rasoulouniriana, D., Tal, L., Netanely, D., Ron Shamir, A., Blau, R., Feinmesser, M., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2944 · Cited by 36

Pre‐existing heterologous T‐cell immunity and neoantigen immunogenicity

Leng, Q., Tarbe, M., Long, Q., & Wang, F. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1111 · Cited by 36

Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy

Amon, L., Hatscher, L., Heger, L., Dudziak, D., & Lehmann, C. H. K. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12070663 · Cited by 37

Combining therapeutic vaccines with chemo- and immunotherapies in the treatment of cancer

Kerr, M. D., McBride, D. A., Chumber, A. K., & Shah, N. J. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1811673 · Cited by 40

Human TYRP1: Two functions for a single gene?

Gautron, A., Migault, M., Bachelot, L., Corre, S., Galibert, M., & Gilot, D. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12951 · Cited by 34

Employing Drug Delivery Strategies to Overcome Challenges Using TLR7/8 Agonists for Cancer Immunotherapy

Varshney, D., Qiu, S. Y., Graf, T. P., & McHugh, K. J. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00620-x · Cited by 40

Photothermal Therapy Combined with Neoantigen Cancer Vaccination for Effective Immunotherapy against Large Established Tumors and Distant Metastasis

Nam, J., Son, S., Park, K. S., & Moon, J. J. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100093 · Cited by 36

Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases

Rouf, N. Z., Biswas, S., Tarannum, N., Oishee, L. M., & Muna, M. M. (2022) · RNA Biology · doi:10.1080/15476286.2022.2055923 · Cited by 39

Therapeutic Vaccines Targeting Neoantigens to Induce T-Cell Immunity against Cancers

Pao, S.-C., Chu, M.-T., & Chung, W. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040867 · Cited by 39

Deep Tumor Penetrating Gold Nano‐Adjuvant for NIR‐II‐Triggered In Situ Tumor Vaccination

Chen, A., Wu, L., Luo, Y., Lu, S., Wang, Y., Zhou, Z., Zhou, D., Xie, Z., & Yue, J. (2022) · Small · doi:10.1002/smll.202200993 · Cited by 36

Safety and Activity of PolyPEPI1018 Combined with Maintenance Therapy in Metastatic Colorectal Cancer: an Open-Label, Multicenter, Phase Ib Study

Hubbard, J. M., Tőke, E. R., Moretto, R., Graham, R. P., Youssoufian, H., Lőrincz, O., Molnár, L., Csiszovszki, Z., Mitchell, J. L., Wessling, J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0112 · Cited by 36

Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma

Mohsen, M. O., Speiser, D. E., Michaux, J., Pak, H., Stevenson, B. J., Vogel, M., Inchakalody, V. P., de Brot, S., Dermime, S., Coukos, G., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002927 · Cited by 36

Nanodrugs Targeting T Cells in Tumor Therapy

Haist, M., Mailänder, V., & Bros, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.912594 · Cited by 36

A Potent Micron Neoantigen Tumor Vaccine GP‐Neoantigen Induces Robust Antitumor Activity in Multiple Tumor Models

Jing, Z., Wang, S., Xu, K., Tang, Q., Li, W., Zheng, W., Shi, H., Su, K., Liu, Y., & Hong, Z. (2022) · Advanced Science · doi:10.1002/advs.202201496 · Cited by 35

Vaccination-based immunotherapy to target profibrotic cells in liver and lung

Sobecki, M., Chen, J., Krzywińska, E., Nagarajan, S., Fan, Z., Nelius, E., Rodríguez, J. M. M., Seehusen, F., Hussein, A., Moschini, G., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2022.08.012 · Cited by 38

Making It Personal: Neoantigen Vaccines in Metastatic Melanoma

Hellmann, M. D., & Snyder, A. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.001 · Cited by 37

In vivo imaging of the immune response upon systemic RNA cancer vaccination by FDG-PET

Pektor, S., Hilscher, L., Walzer, K. C., Miederer, I., Bausbacher, N., Loquai, C., Schreckenberger, M., Şahin, U., Diken, M., & Miederer, M. (2018) · EJNMMI Research · doi:10.1186/s13550-018-0435-z · Cited by 36

Vaccination With a FAT1-Derived B Cell Epitope Combined With Tumor-Specific B and T Cell Epitopes Elicits Additive Protection in Cancer Mouse Models

Grandi, A., Fantappiè, L., Irene, C., Valensin, S., Tomasi, M., Stupia, S., Corbellari, R., Caproni, E., Zanella, I., Isaac, S. J., et al. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00481 · Cited by 35

A library of Neo Open Reading Frame peptides (NOPs) as a sustainable resource of common neoantigens in up to 50% of cancer patients

Köster, J., & Plasterk, R. H. A. (2019) · Scientific Reports · doi:10.1038/s41598-019-42729-2 · Cited by 35

neoepiscope improves neoepitope prediction with multivariant phasing

Wood, M. A., Nguyen, A., Struck, A. J., Ellrott, K., Nellore, A., & Thompson, R. F. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz653 · Cited by 35

New emerging targets in cancer immunotherapy: the role of neoantigens

Mattos‐Arruda, L. D., Blanco-Heredia, J., Aguilar‐Gurrieri, C., Carrillo, J., & Blanco, J. (2019) · ESMO Open · doi:10.1136/esmoopen-2020-000684 · Cited by 35

Therapeutic cancer vaccines for pediatric malignancies: advances, challenges, and emerging technologies

Olsen, H. E., Lynn, G. M., Valdes, P. A., Cerecedo-Lopez, C. D., Ishizuka, A. S., Arnaout, O. M., Bi, W. L., Peruzzi, P. P., Chiocca, E. A., Friedman, G. K., et al. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab027 · Cited by 35

Identification and Targeting of Mutant Peptide Neoantigens in Cancer Immunotherapy

Verdon, D. J., & Jenkins, M. R. (2021) · Cancers · doi:10.3390/cancers13164245 · Cited by 36

Facts and Hopes for Immunotherapy in Renal Cell Carcinoma

Yao, C., Zhang, T., Wu, T., & Brugarolas, J. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2372 · Cited by 35

Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64)

Vavolizza, R. D., Petroni, G. R., Mauldin, I. S., Chianese‐Bullock, K. A., Olson, W. C., Smith, K. T., Dengel, L. T., Haden, K., Grosh, W. W., Kaur, V., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005424 · Cited by 35

Neoantigens as potential vaccines in hepatocellular carcinoma

Repáraz, D., Ruiz, M., Llópiz, D., Silva, L., Vercher, E., Aparicio, B., Egea, J., Tamayo, I., Hervás‐Stubbs, S., García-Balduz, J., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003978 · Cited by 34

Antigen discovery for the development of cancer immunotherapy

Ahn, R., Cui, Y., & White, F. M. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101733 · Cited by 33

Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression

Ramirez-Valdez, R. A., Baharom, F., Khalilnezhad, A., Fussell, S. C., Hermans, D., Schrager, A. M., Tobin, K. K. S., Lynn, G. M., Khalilnezhad, S., Ginhoux, F., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112599 · Cited by 37

Nanoengineered coordination polymers boost cancer immunotherapy

Li, X., Yamazaki, T., Ebara, M., Shirahata, N., & Hanagata, N. (2023) · Materials Today · doi:10.1016/j.mattod.2023.06.001 · Cited by 34

Advancements in Melanoma Treatment: A Review of PD-1 Inhibitors, T-VEC, mRNA Vaccines, and Tumor-Infiltrating Lymphocyte Therapy in an Evolving Landscape of Immunotherapy

Mehta, A., Motavaf, M., Nebo, I. D., Luyten, S., Osei-Opare, K. D., & Gru, A. A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041200 · Cited by 38

Immunotherapy in ovarian cancer: fake news or the real deal?

Marth, C., Wieser, V. E., Tsibulak, I., & Zeimet, A. G. (2019) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2018-000011 · Cited by 35

Automated Flow Synthesis of Tumor Neoantigen Peptides for Personalized Immunotherapy

Truex, N. L., Holden, R. L., Wang, B., Chen, P., Hanna, S., Hu, Z., Shetty, K. S., Olive, O., Neuberg, D. S., Hacohen, N., et al. (2020) · Scientific Reports · doi:10.1038/s41598-019-56943-5 · Cited by 35

Hallmarks of Splicing Defects in Cancer: Clinical Applications in the Era of Personalized Medicine

Rahman, M. A., Nasrin, F., Bhattacharjee, S., & Nandi, S. (2020) · Cancers · doi:10.3390/cancers12061381 · Cited by 32

A REVIEW ON CORONAVIRUS DISEASE 2019

Usha, B., C, E. V., & K, V. N. (2020) · British Journal of Medical and Health Research · doi:10.46624/bjmhr.2020.v7.i5.005 · Cited by 34

Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies

Kast, F., Klein, C., Umaña, P., Gros, A., & Gasser, S. (2021) · OncoImmunology · doi:10.1080/2162402x.2020.1869389 · Cited by 34

Synergistic Activation of Antitumor Immunity by a Particulate Therapeutic Vaccine

Mai, J., Li, Z., Xia, X., Zhang, J., Li, J., Liu, H., Shen, J., Ramirez, M., Li, F., Li, Z., et al. (2021) · Advanced Science · doi:10.1002/advs.202100166 · Cited by 32

Proteogenomic identification of an immunogenic HLA class I neoantigen in mismatch repair–deficient colorectal cancer tissue

Hirama, T., Tokita, S., Nakatsugawa, M., Murata, K., Nannya, Y., Matsuo, K., Inoko, H., Hirohashi, Y., Hashimoto, S., Ogawa, S., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.146356 · Cited by 34

Development of neoantigens: from identification in cancer cells to application in cancer vaccines

Ebrahimi, N., Akbari, M., Ghanaatian, M., moghaddam, P. R., Adelian, S., Boroujeni, M. B., Yazdani, E., Ahmadi, A., & Hamblin, M. R. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1951246 · Cited by 37

High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4+ and CD8+ neoantigen-specific T cells to promote antitumor immunity

Hernandez, R., LaPorte, K. M., Hsiung, S., Savio, A. S., & Malek, T. R. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002865 · Cited by 35

Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma

Peri, A., Greenstein, E., Alon, M., Pai, J. A., Dingjan, T., Reich-Zeliger, S., Barnea, E., Barbolin, C., Levy, R., Arnedo-Pac, C., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci129466 · Cited by 36

Neoantigen Cancer Vaccines: Generation, Optimization, and Therapeutic Targeting Strategies

Reynolds, C. R., Tran, S., Jain, M., & Narendran, A. (2022) · Vaccines · doi:10.3390/vaccines10020196 · Cited by 36

Rituximab‐treated patients with lymphoma develop strong CD8 T‐cell responses following COVID ‐19 vaccination

Riise, J., Meyer, S., Blaas, I., Chopra, A., Tran, T. T., Delić-Šarac, M., Hestdalen, M. L., Brodin, E. E., Rustad, E. H., Dai, K., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18149 · Cited by 32

MHC II immunogenicity shapes the neoepitope landscape in human tumors

Kim, J. Y., Cha, H., Kim, K., Sung, C., An, J., Bang, H., Kim, H., Yang, J. O., Chang, S., Shin, I., et al. (2023) · Nature Genetics · doi:10.1038/s41588-022-01273-y · Cited by 33

The mRNA Vaccine Technology Era and the Future Control of Parasitic Infections

You, H., Jones, M. K., Gordon, C. A., Arganda, A. E., Cai, P., Al-Wassiti, H., Pouton, C. W., & McManus, D. P. (2023) · Clinical Microbiology Reviews · doi:10.1128/cmr.00241-21 · Cited by 39

Neoantigen-directed therapeutics in the clinic: where are we?

Lybaert, L., Thielemans, K., Feldman, S. A., van der Burg, S. H., Bogaert, C., & Ott, P. A. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.02.004 · Cited by 35

The HLA Ligand Atlas - A resource of natural HLA ligands presented on benign tissuesPreprint

Marcu, A., Bichmann, L., Kuchenbecker, L., Kowalewski, D. J., Freudenmann, L. K., Backert, L., Mühlenbruch, L., Szolek, A., Lübke, M., Wagner, P., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/778944 · Cited by 34

Lynch syndrome cancer vaccines: A roadmap for the development of precision immunoprevention strategies

Sei, S., Ahadova, A., Keskin, D. B., Bohaumilitzky, L., Gebert, J. F., Doeberitz, M. V. K., Lipkin, S. M., & Kloor, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1147590 · Cited by 36

Progress in nanoparticle-based regulation of immune cells

Fan, Y.-N., Zhao, G., Zhang, Y., Ye, Q., Sun, Y., Shen, S., Liu, Y., Xu, C., & Wang, J. (2023) · Medical Review · doi:10.1515/mr-2022-0047 · Cited by 35

Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells

Nelde, A., Schuster, H., Heitmann, J. S., Bauer, J., Maringer, Y., Zwick, M., Volkmer, J.-P., Chen, J. Y., Stanger, A. M. P., Lehmann, A., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0020 · Cited by 35

Engineered Bacteriophage-Based In Situ Vaccine Remodels a Tumor Microenvironment and Elicits Potent Antitumor Immunity

Lei, L., Yan, J., Xin, K., Li, L., Sun, Q., Wang, Y., Chen, T., Wu, S., Shao, J., Liu, B., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c00413 · Cited by 33

Population-level distribution and putative immunogenicity of cancer neoepitopes

Wood, M. A., Paralkar, M., Paralkar, M. P., Nguyen, A., Struck, A. J., Ellrott, K., Margolin, A. A., Nellore, A., & Thompson, R. F. (2018) · BMC Cancer · doi:10.1186/s12885-018-4325-6 · Cited by 35

Novel tools to assist neoepitope targeting in personalized cancer immunotherapy

Saini, S. K., Rekers, N. H., & Hadrup, S. R. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx544 · Cited by 33

Big Data Approaches for Modeling Response and Resistance to Cancer Drugs

Jiang, P., Sellers, W. R., & Liu, X. S. (2018) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-080917-013350 · Cited by 32

Next Generation Cancer Vaccines—Make It Personal!

Terbuch, A., & Lopez, J. S. (2018) · Vaccines · doi:10.3390/vaccines6030052 · Cited by 33

Insights Into Mechanisms of Tumor and Immune System Interaction: Association With Wound Healing

Ponomarev, А. V., & Shubina, I. Z. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01115 · Cited by 36

Development of tumour peptide vaccines: From universalization to personalization

Ma, M., Liu, J., Jin, S., & Wang, L. (2020) · Scandinavian Journal of Immunology · doi:10.1111/sji.12875 · Cited by 32

Multifunctional Immunoadjuvants for Use in Minimalist Nucleic Acid Vaccines

Abbasi, S., & Uchida, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050644 · Cited by 33

Personalized combination nano-immunotherapy for robust induction and tumor infiltration of CD8+ T cells

Park, K. S., Nam, J., Son, S., & Moon, J. J. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120844 · Cited by 34

The development and improvement of ribonucleic acid therapy strategies

Zhao, Y., Shu, R., & Liu, J. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.09.002 · Cited by 33

Vaccine-Based Immunotherapy for Head and Neck Cancers

Beyaert, S. P., Machiels, J., & Schmitz, S. (2021) · Cancers · doi:10.3390/cancers13236041 · Cited by 32

Tumor neoantigens: Novel strategies for application of cancer immunotherapy

Guan, H., Wu, Y., Li, L., Yang, Y., Qiu, S., Zhao, Z., Chu, X., He, J., Chen, Z., ZHANG, Y., et al. (2023) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.029924 · Cited by 34

Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data

Liu, S., Tang, Q.-J., Huang, J., Zhan, M., Zhao, W., Yang, X., Li, Y., Qiu, L., Zhang, F., Lu, L., et al. (2021) · Aging · doi:10.18632/aging.202811 · Cited by 33

Harnessing the Immune System with Cancer Vaccines: From Prevention to Therapeutics

Le, I., Dhandayuthapani, S., Chacon, J. A., Eiring, A. M., & Gadad, S. S. (2022) · Vaccines · doi:10.3390/vaccines10050816 · Cited by 32

Mannose and Hyaluronic Acid Dual-Modified Iron Oxide Enhances Neoantigen-Based Peptide Vaccine Therapy by Polarizing Tumor-Associated Macrophages

Nie, Y., Shi, L. D., Zhang, Y., Guo, Y., & Gu, H. (2022) · Cancers · doi:10.3390/cancers14205107 · Cited by 33

MC38 colorectal tumor cell lines from two different sources display substantial differences in transcriptome, mutanome and neoantigen expression

Schrörs, B., Hos, B. J., Yildiz, I., Löwer, M., Lang, F., Holtsträter, C., Becker, J., Vormehr, M., Şahin, U., OSSENDORP, F. A., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1102282 · Cited by 38

Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma

Mørk, S. K., Skadborg, S. K., Albieri, B., Draghi, A., Bol, K. F., Kadivar, M., Westergaard, M. C. W., Granhøj, J. S., Borch, A., Viborg, N., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-008817 · Cited by 33

mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends

Gao, Y., Yang, L., Li, Z., Peng, X., & Li, H. (2024) · Biomarker Research · doi:10.1186/s40364-024-00644-3 · Cited by 34

Activation of CD8+ T Cell Responses after Melanoma Antigen Targeting to CD169+ Antigen Presenting Cells in Mice and Humans

van Dinther, D., Venegas, M. L., Veninga, H., Olesek, K., Hoogterp, L., Revet, M., Ambrosini, M., Kalay, H., Stöckl, J., van Kooyk, Y., et al. (2019) · Cancers · doi:10.3390/cancers11020183 · Cited by 32

Transcutaneous delivery of DNA/mRNA for cancer therapeutic vaccination

Sun, X., Zeng, L., & Huang, Y. (2019) · The Journal of Gene Medicine · doi:10.1002/jgm.3089 · Cited by 34

At the bench: Engineering the next generation of cancer vaccines

Shae, D., Baljon, J. J., Wehbe, M., Becker, K. W., Sheehy, T. L., & Wilson, J. T. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.5bt0119-016r · Cited by 32

The Ways of Isolating Neoantigen-Specific T Cells

Li, Q., & Ding, Z. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01347 · Cited by 31

CIITA-Transduced Glioblastoma Cells Uncover a Rich Repertoire of Clinically Relevant Tumor-Associated HLA-II Antigens

Forlani, G., Michaux, J., Pak, H., Huber, F., Joseph, E. L. M., Ramia, E., Stevenson, B. J., Linnebacher, M., Accolla, R. S., & Bassani‐Sternberg, M. (2020) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra120.002201 · Cited by 33

Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects

Zhong, C. F., Li, Y., Yang, J., Jin, S., Chen, G., Li, D., Fan, X., & Lin, H. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.589680 · Cited by 32

Natural Killer Cells and Dendritic Cells: Expanding Clinical Relevance in the Non-Small Cell Lung Cancer (NSCLC) Tumor Microenvironment

Ahluwalia, P. K., Ahluwalia, M., Mondal, A. K., Sahajpal, N., Kota, V. K., Rojiani, M. V., & Kolhe, R. B. (2021) · Cancers · doi:10.3390/cancers13164037 · Cited by 34

Antimetastatic defense by CD8+ T cells

de Lara, P. T., Castañón, H., Sterpi, M., & van den Broek, M. F. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.10.006 · Cited by 32

Bioinspired Spatiotemporal Management toward RNA Therapies

Ma, Y., Li, S., Lin, X., & Chen, Y. (2023) · ACS Nano · doi:10.1021/acsnano.3c08219 · Cited by 32

Antibody-based Delivery of TNF to the Tumor Neovasculature Potentiates the Therapeutic Activity of a Peptide Anticancer Vaccine

Probst, P., Stringhini, M., Ritz, D., Fugmann, T., & Neri, D. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1728 · Cited by 34

PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting

Saxena, M., Marron, T. U., Kodysh, J., Finnigan, J. P., Onkar, S., Kaminska, A., Tuballes, K., Guo, R., Sabado, R. L., Meseck, M., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0934 · Cited by 28

Impact of Age-, Cancer- and Treatment-Driven Inflammation on T Cell Function and Immunotherapy

Quinn, K. M., Kartikasari, A. E. R., Cooke, R. E., Koldej, R. M., Ritchie, D. S., & Plebanski, M. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5mr0520-466r · Cited by 31

Membranal and Blood‐Soluble HLA Class II Peptidome Analyses Using Data‐Dependent and Independent Acquisition

Ritz, D., Sani, E., Dêbiec, H., Ronco, P. M., Neri, D., & Fugmann, T. (2018) · PROTEOMICS · doi:10.1002/pmic.201700246 · Cited by 31

Bystander responses impact accurate detection of murine and human antigen-specific CD8+ T cells

Martin, M. D., Jensen, I. J., Ishizuka, A. S., Lefebvre, M. N., Shan, Q., Xue, H., Harty, J. T., Seder, R. A., & Badovinac, V. P. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124443 · Cited by 31

Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display

Wickström, S. L., Lövgren, T., Volkmar, M., Reinhold, B. B., Duke‐Cohan, J. S., Hartmann, L., Rebmann, J., Müeller, A., Melief, J., Maas, R. R., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02766 · Cited by 32

Heterogeneity of neoantigen landscape between primary lesions and their matched metastases in lung cancer

Jiang, T., Su, C., Cheng, R., Pan, Y., Zhang, H., He, J., He, Y., Tang, R., Ren, S., & Zhou, C. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.03.03 · Cited by 33

Combinatorial Immunotherapies for Metastatic Colorectal Cancer

Janssen, E., Subtil, B., Ortiz, F. D. L. J., Verheul, H. M. W., & Tauriello, D. V. F. (2020) · Cancers · doi:10.3390/cancers12071875 · Cited by 31

Role of in silico structural modeling in predicting immunogenic neoepitopes for cancer vaccine development

Zaidi, N., Soban, M., Chen, F., Kinkead, H. L., Mathew, J., Yarchoan, M. M., Armstrong, T. D., Haider, S. M., & Jaffee, E. M. (2020) · JCI Insight · doi:10.1172/jci.insight.136991 · Cited by 29

Personal Neoantigen Cancer Vaccines: A Road Not Fully Paved

Fritsch, E. F., Burkhardt, U. E., Hacohen, N., & Wu, C. J. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0526 · Cited by 31

mRNA-based modalities for infectious disease management

Zhang, M., Hussain, A., Yang, H., Zhang, J., Liang, X., & Huang, Y. (2022) · Nano Research · doi:10.1007/s12274-022-4627-5 · Cited by 35

What’s next for cancer vaccines

Adamik, J., & Butterfield, L. H. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo4632 · Cited by 31

An immunogenic personal neoantigen vaccine for patients with melanoma

Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936

Abstract CT022: IVAC® MUTANOME - A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma

Miller, M., Loquai, C., Kloke, B., Attig, S., Bidmon, N., Bolte, S., Bukur, V., Derhovanessian, E., Diekmann, J., Filbry, A., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-ct022

Precision T-cell therapy targets tumours

Melief, C. J. M. (2017) · Nature · doi:10.1038/nature23093 · Cited by 28

Abstract PR02: A personalized neoantigen vaccine in patients with high risk melanoma

Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Fritsch, E. F., Hacohen, N., & Wu, C. J. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.imm2016-pr02

Personalized melanoma vaccines

Kelly, P. N. (2017) · Science · doi:10.1126/science.357.6353.769-b